证券代码：002317 公告编号：2025-103 广东众生药业股份有限公司 第八届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十八次 会议的会议通知于 2025 年 10 月 20 日以专人和电子邮件形式送达全体董事，会 议于 2025 年 10 月 30 日在公司会议室以现场和通讯表决方式召开。本次会议应 出席董事 9 人，实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监 事、董事会秘书列席会议。本次会议的召集和召开符合法律、法规和《公司章程》 的有关规定。经与会董事认真审议，以记名投票方式表决，做出如下决议： 表决结果：9 票同意，0 票反对，0 票弃权。 一、审议通过了《公司 2025 年第三季度报告》。 表决结果：9 票同意，0 票反对，0 票弃权。 备注：具体内容详见信息披露媒体：《证券时报》《上海证券报》和巨潮资讯 网（www.cninfo.com.cn）。 二、审议通过了《关于使用闲置自有资金进行委托理财的议案》。 备注：《关于使用闲置自有 ...

南财智讯10月30日电，众生药业公告，公司及子公司拟使用不超过人民币4.00亿元的闲置自有资金进行 委托理财，投资于安全性高、流动性好的金融机构销售的理财类产品。该事项已由公司第八届董事会第 二十八次会议审议通过，无需提交股东大会审议。资金在12个月内可滚动使用，自董事会审议通过之日 起生效。 ...

众生药业公告，第三季度营收为5.89亿元，同比增长8.35%；净利润为6268.22万元，同比增长2.10%。 前三季度营收为18.89亿元，同比下降1.01%；净利润为2.51亿元，同比增长68.40%。 ...

证券代码：002317 证券简称：众生药业 公告编号：2025-105 广东众生药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 广东众生药业股份有限公司 2025 年第三季度报告 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 广东众生药业股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 589,023,962.64 | 8.35% ...

证券日报网讯众生药业（002317）10月29日在互动平台回答投资者提问时表示，公司始终重视药品的国 外市场机会，积极推动产品在海外临床申请和注册，目前已获得澳门特别行政区政府药物监督管理局签 发的一类创新药物昂拉地韦片(商品名：安睿威)成药登记证书，标志着公司具备了在澳门销售该药品的 资格。昂拉地韦片为处方药，其境外流通与购买必须严格遵守属地监管法规及医疗诊疗规范，需由当地 具备资质的医疗机构根据患者具体病情开具处方后，通过合规医疗渠道获取。 ...

Core Viewpoint - The company is actively advancing the commercialization of its antiviral drug, Olanidovir tablets, which shows strong efficacy against various strains of influenza, including those resistant to other treatments [2]. Group 1: Product Development - The company is progressing with the commercialization of Olanidovir tablets (brand name: Anruwei®) for the treatment of adult patients with uncomplicated influenza A [2]. - Preclinical studies indicate that Olanidovir has strong inhibitory activity against multiple influenza virus strains, including those resistant to Oseltamivir and Baloxavir [2]. - The Phase III clinical trial results comparing Olanidovir tablets with Oseltamivir capsules and placebo for treating adult influenza A have shown positive outcomes, achieving the predefined primary efficacy endpoint with good safety [2]. Group 2: Clinical Efficacy - Subgroup analysis from the Phase III trial suggests that Olanidovir significantly shortens the time to relief from influenza symptoms compared to placebo for H1 and H3 subtype strains [2].

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced a decline of 2.05% on October 28, with a current price of 17.66 CNY per share and a total market capitalization of 15.01 billion CNY. The company has seen a year-to-date stock price increase of 47.78% but has faced recent declines over various trading periods [1]. Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical reported a revenue of 1.3 billion CNY, a year-on-year decrease of 4.74%. However, the net profit attributable to shareholders increased significantly by 114.96% to 188 million CNY [2]. - The company has distributed a total of 2.019 billion CNY in dividends since its A-share listing, with 502 million CNY distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Zhongsheng Pharmaceutical was 89,900, a decrease of 1.32% from the previous period. The average number of circulating shares per shareholder increased by 1.33% to 8,470 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 9.1731 million shares, marking its entry as a new shareholder. Other notable shareholders include Xingquan He Feng Mixed Fund and Xingquan Multi-Dimensional Value Mixed Fund, which have reduced their holdings [3]. Market Activity - The stock has been active on the "Dragon and Tiger List" three times this year, with the most recent appearance on September 22, where it recorded a net buy of -164 million CNY [1]. - The stock has seen significant trading activity, with a total transaction volume of 231 million CNY on the day of the report, and a turnover rate of 1.70% [1]. Business Overview - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals. Its revenue composition includes 53.03% from traditional Chinese medicine sales, 38.12% from chemical drug sales, and smaller contributions from other segments [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the traditional Chinese medicine sub-sector, and is involved in various concept boards including pharmaceutical e-commerce and NMN concepts [2].

Core Viewpoint - Zhongsheng Pharmaceutical (002317) announced that its wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the raw material drug Polyvinyl Alcohol [1] Company Summary - The approval pertains to the chemical raw material drug Polyvinyl Alcohol, indicating a significant regulatory milestone for the company [1] - This development may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [1]

证券代码：002317 公告编号：2025-102 广东众生药业股份有限公司 关于全资子公司获得聚乙烯醇 化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）全资子公司广东先强药业 有限公司于近日收到国家药品监督管理局核准签发的原料药聚乙烯醇《化学原料 药上市申请批准通知书》。现就相关情况公告如下： 一、《化学原料药上市申请批准通知书》的主要内容 登记号：Y20240000527 通知书编号：2025YS00937 生产企业：名称：广东先强药业有限公司，地址：广州市从化经济开发区工 业大道 6 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、药品简介 聚乙烯醇属高分子聚合物，具有亲水性和成膜性，在适宜浓度下，能起到类 似人工泪液的作用，能为眼表持续提供润滑与保护。聚乙烯醇滴眼液可作为一种 润滑剂预防或治疗眼部干涩、异物感、眼疲劳等刺激症状或改善眼部的干燥症状。 根据米内网数据库显示，聚乙烯醇滴眼液 2022 至 2024 ...

Core Viewpoint - The announcement highlights that Zhongsheng Pharmaceutical's subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing authorization of the raw material drug Polyvinyl Alcohol, which is used in eye drops to alleviate symptoms of dryness and irritation [1] Company Summary - Zhongsheng Pharmaceutical's subsidiary has been granted a marketing authorization for Polyvinyl Alcohol, a high molecular polymer with hydrophilic and film-forming properties [1] - The approved product, Polyvinyl Alcohol eye drops, serves as a lubricant to prevent or treat symptoms such as dryness, foreign body sensation, and eye fatigue [1] Industry Summary - Polyvinyl Alcohol is recognized for its application in ophthalmic solutions, providing lubrication and protection to the eye surface [1] - The approval of this product indicates a potential growth opportunity in the ophthalmic market, particularly for treatments addressing dry eye symptoms [1]